Photo by visuals from unsplash
ABSTRACT Immune-modulating medications for inflammatory bowel diseases (IBD) have been associated with suboptimal vaccine responses. There is conflicting data with SARS-CoV-2 vaccination. We therefore assessed SARS-CoV-2 vaccine immunogenicity at 2… Click to show full abstract
ABSTRACT Immune-modulating medications for inflammatory bowel diseases (IBD) have been associated with suboptimal vaccine responses. There is conflicting data with SARS-CoV-2 vaccination. We therefore assessed SARS-CoV-2 vaccine immunogenicity at 2 weeks post second mRNA vaccine in 29 IBD patients compared to 12 normal healthy donors (NHD). We observed reduced humoral immunity in IBD patients on infliximab. However, we observed no difference in humoral and cell-mediated immunity in IBD patients on infliximab with a thiopurine or vedolizumab compared to NHDs. This is the first study to demonstrate comparable cell-mediated immunity to SARS-CoV-2 vaccination in IBD patients treated with different immune-modulating medications.
Journal Title: Clinical and translational gastroenterology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!